Camrelizumab Plus Famitinib Demonstrates Early Antitumor Activity in Advanced Melanoma
Source: OncLive, June 2023
Camrelizumab combined with famitinib elicited responses and was well tolerated in patients with advanced melanoma previously exposed to an immune checkpoint inhibitor regimen.
Administration of the PD-L1 inhibitor camrelizumab combined with the selective multikinase inhibitor famitinib elicited responses and was well tolerated in patients with advanced acral or mucosal melanoma previously exposed to an immune checkpoint inhibitor (ICI) regimen, according to data from a phase 2 trial (NCT05051865)presented at the 2023 ASCO Annual Meeting.
Of the 17 efficacy evaluable patients with prior ICI exposure, the overall response rate (ORR) with the regimen was 17.6%; this consisted of 2 patients with a confirmed partial response (PR) and 1 patient with an unconfirmed PR. Eight patients (47.1%) had stable disease (SD) and 6 patients (35.3%) experienced progressive disease (PD). The best percentage change in target lesion size from baseline was approximately 50% in 1 patient with acral melanoma. The disease control rate (DCR) was 64.7% in this population.